Market Overview

Galectin Therapeutics Says Anti-Galectin Drug Effective in Preclinical Studies

Related GALT
Galectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference
Galectin Therapeutics Still A Favorite Pick Of H.C. Wainwright Analysts
Galectin Therapeutics, Inc. Executive Chairman Jim Czirr to Be Interviewed on "The Big Biz ... (GuruFocus)

Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease. Treatment of diabetic mice with GR-MD-02 was found to reverse the primary kidney disease associated with diabetes, called diabetic nephropathy, the leading cause of kidney failure, dialysis and kidney transplant. GR-MD-02 is the Company's lead galectin inhibitor in development for the treatment of liver fibrosis, including non-alcoholic steatohepatitis (NASH) liver disease.

Posted-In: News


Related Articles (GALT)

Get Benzinga's Newsletters